Survodutide: The Glucagon-GLP-1 Dual Agonist Being Studied for Obesity and Liver Disease

The waiting room conversation has changed. A few years ago patients asked about one weekly injection by brand name. Now they arrive with a word they can barely pronounce, survodutide, and a screenshot of a headline about livers. The search spike is easy to explain: phase 2 results published in 2023 and 2024 showed that this single molecule shifted body weight and liver biopsies at the same time, and a large phase 3 program is now reading out in stages, keeping it in the news as of early 2026.

What makes survodutide interesting is not that it is another GLP-1 drug. It is that it deliberately recruits glucagon, a hormone most people associate with raising blood sugar, and puts it to work in the liver. That is either a clever two-for-one or a balancing act, depending on how the larger trials land.

This piece walks through what the molecule does, what the trials have actually measured, how strong that evidence is, and where the viral claims part ways with the data.

Why is survodutide trending right now? What changed recently

Three dated events built the current wave of interest. The first came in late 2023, when the phase 2 obesity trial was published in The Lancet Diabetes & Endocrinology. A phase 2 trial is a mid-sized study that tests whether a drug works and at what level, before the much larger phase 3 studies that regulators rely on. That paper reported that adults living with obesity, but without diabetes, lost up to roughly 15 percent of their body weight over 46 weeks on survodutide, against under 3 percent on placebo.

The second event landed in June 2024 in The New England Journal of Medicine. A separate phase 2 trial in people with metabolic dysfunction-associated steatohepatitis (MASH), the inflamed and scarring form of fatty liver disease, found that up to 83 percent of treated participants showed improvement in liver inflammation on biopsy without their scarring getting worse, compared with 18 percent on placebo. Liver specialists do not see numbers like that often, and the paper circulated widely.

Third, the US Food and Drug Administration granted survodutide Breakthrough Therapy designation for MASH with fibrosis in 2024. That label does not mean approval; it means the agency agrees the early data look promising enough to speed up review conversations.

Since then, the phase 3 program, called SYNCHRONIZE for obesity and LIVERAGE for liver disease, has been enrolling and completing trials, and each top-line announcement produces a fresh news cycle. The honest summary as of early 2026: the peer-reviewed evidence everyone can read in full is still phase 2, and the phase 3 details are arriving piece by piece. Both of the trial publications are indexed on PubMed, which is the best place to check what has actually been published rather than announced.

What is survodutide, exactly?

Survodutide, also known by its development code BI 456906, is a synthetic peptide. A peptide is a short chain of amino acids, the same building blocks that make up proteins and hormones in your body. Survodutide was built on the backbone of natural glucagon and then modified so that it also fits the GLP-1 receptor, and so that it lingers in the bloodstream for days rather than minutes.

Two terms matter here. A receptor is a docking site on the surface of a cell; when the right molecule attaches, the cell changes its behavior. An agonist is a molecule that switches a receptor on. So a dual glucagon/GLP-1 receptor agonist is a single drug that turns on two different hormone receptors at once. Survodutide is designed to activate them in a deliberate ratio, with the glucagon signal dialed to be meaningful but not dominant.

It is given by injection under the skin, the same route used by the approved GLP-1 medicines, and its long half-life (the time it takes the body to clear half of a dose) is what allows the extended interval between injections used in the trials. The exact interval and dose levels are a matter for the trial protocols and, eventually, a prescribing label; they are not the subject of this article.

The molecule was developed through a partnership between a European pharmaceutical company and a Danish peptide specialist, and it sits in the same broad family as semaglutide and tirzepatide, which also began life as engineered gut-hormone peptides. The difference is the second receptor it chooses. Tirzepatide pairs GLP-1 with GIP, another gut hormone; survodutide pairs GLP-1 with glucagon, a hormone whose main address is the liver.

How does survodutide work? The GLP-1 half

GLP-1 stands for glucagon-like peptide-1, a hormone released by cells in the small intestine within minutes of eating. Its job is to tell the body that food has arrived. It prompts the pancreas to release insulin when blood sugar is rising, slows the rate at which the stomach empties, and sends signals to the brainstem and hypothalamus that register as fullness.

Natural GLP-1 is destroyed within about two minutes by an enzyme in the blood. Every GLP-1 medicine, from liraglutide onward, works by mimicking the hormone while resisting that enzyme, so the fullness signal stays switched on far longer than a meal would ever produce. That is why people on these drugs describe quieter food thoughts and smaller portions rather than a feeling of being dieted.

Survodutide’s GLP-1 activity is expected to deliver the same package of effects: slower stomach emptying, reduced appetite, and glucose-dependent insulin release, meaning insulin rises when sugar is high and eases off when it is not. That last property is why GLP-1 drugs on their own rarely cause dangerously low blood sugar in people who are not also taking insulin or sulfonylureas.

The GLP-1 pathway also explains the most familiar side effects of the class. Slower stomach emptying is useful for appetite but it is also what produces nausea, bloating, constipation and, for some, vomiting, especially when the dose is first increased. Cleveland Clinic’s overview of GLP-1 agonists describes these as the most common complaints across the entire class, and the survodutide trials followed that pattern closely. Understanding the GLP-1 half is really understanding what survodutide shares with the medicines already in pharmacies. The novelty lives in the other half.

The glucagon half: why add a hormone that raises blood sugar?

Glucagon is the hormone your pancreas releases when blood sugar drops. It tells the liver to release stored glucose and to make new glucose, which is why injectable glucagon is a rescue treatment for severe hypoglycemia. On its face, adding it to a weight-loss drug sounds backwards.

The appeal lies in what else glucagon does in the liver. It increases the breakdown of fat, pushes liver cells to burn fatty acids for fuel, and raises overall energy expenditure by a modest amount. In animal and early human studies, sustained glucagon receptor activation reduced liver fat and slightly increased the number of calories burned at rest. For a disease like MASH, where the core problem is too much fat sitting inside liver cells and provoking inflammation, that is a tempting lever.

The glucose problem is handled by the partner. GLP-1 activation raises insulin and lowers glucagon’s effect on blood sugar, so when the two signals are balanced correctly the net effect on glucose is neutral or slightly favorable. In the phase 2 obesity trial, average blood sugar markers did not deteriorate, and the dual agonist approach is also being tested in people with type 2 diabetes to confirm that balance holds.

Where the balance shows up most clearly is in the design choice itself. Survodutide was engineered with glucagon activity set below its GLP-1 activity, a middle path between pure GLP-1 drugs and triple agonists such as retatrutide, which add GIP as a third receptor. Whether that particular ratio delivers more liver benefit, more weight loss, or simply more side effects than the alternatives is precisely what phase 3 is meant to answer. Mechanism explains the hypothesis; it does not prove the outcome.

What did the phase 2 obesity trial find?

The obesity study enrolled 387 adults with a body mass index of 27 or higher and no diabetes, randomly assigned them to placebo or one of several dose levels of survodutide, and followed them for 46 weeks. Randomization matters: it is what makes a trial fair, because neither participants nor investigators choose who gets the active drug.

On the main analysis, which counts everyone who started regardless of whether they finished, mean weight change ranged from about 6 percent at the lowest level to about 15 percent at the highest, versus roughly 3 percent on placebo. Among participants who stayed on treatment to the end, the top group averaged closer to 19 percent. Both figures are legitimate, and headlines tend to pick whichever suits the story; the intention-to-treat figure is the more conservative one and the one regulators weight most.

Two details deserve equal billing. First, weight was still falling at week 46 in the higher groups, so the trial likely ended before the full effect was reached. Second, a sizeable minority stopped the drug because of side effects, approaching one in four in the higher-dose groups, driven mainly by nausea and vomiting. The trial used a fast dose-escalation design that the investigators themselves flagged as a probable contributor, and the phase 3 program adopted a slower approach.

Beyond weight, the trial reported improvements in waist circumference, blood pressure and lipid markers broadly in line with what the weight loss itself would predict. It did not measure heart attacks, strokes or deaths; it was far too small and short for that. What it established is that the dual mechanism produces clinically meaningful weight loss in under a year, with tolerability as the open question.

Can survodutide help fatty liver disease? The MASH trial

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease, means excess fat stored in the liver in someone who drinks little or no alcohol. According to the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, it affects roughly a quarter of adults worldwide. MASH is its more serious form, where fat is accompanied by inflammation and injury to liver cells. Over years, that injury can produce fibrosis, the medical term for scar tissue, and eventually cirrhosis.

The phase 2 liver trial enrolled 293 adults with biopsy-confirmed MASH and fibrosis stages 1 to 3, meaning scarring that was present but had not yet become cirrhosis. Participants received placebo or survodutide for 48 weeks and had a second biopsy at the end. The primary endpoint, improvement in MASH without worsening of fibrosis, was met by up to 83 percent on the highest dose level versus 18 percent on placebo. Fibrosis improved by at least one stage in about half of treated participants compared with about a quarter on placebo. Liver fat, measured by MRI, fell by 30 percent or more in the large majority of treated participants.

Why do these numbers run higher than for pure GLP-1 drugs in similar trials? The glucagon action on liver fat is the leading explanation, alongside the weight loss itself. Both mechanisms likely contribute, and the trial cannot separate them.

What the trial could not show is whether these biopsy changes translate into fewer cases of cirrhosis, liver failure or liver cancer. Those outcomes take years to accumulate, which is why the phase 3 LIVERAGE program is designed to run far longer and, in a separate study, to include people who already have compensated cirrhosis. Mayo Clinic’s overview of fatty liver disease is a good plain-language anchor for the condition itself.

What the evidence actually says: a plain grading

Not all evidence weighs the same, and survodutide is a useful case study in reading the labels. Here is how the current body of data grades, strongest to weakest.

Randomized, placebo-controlled phase 2 trials (moderate strength). The obesity and MASH studies were randomized and blinded, which protects against bias, and both were published in peer-reviewed journals. Their limits are size (a few hundred people each), duration (under a year), and the fact that they were designed to pick doses rather than to prove safety at population scale. Phase 2 results in this field have generally held up in phase 3, but the effect size often shrinks somewhat.

Phase 3 top-line announcements (preliminary until published). Company statements describing phase 3 outcomes are real data, but until the full papers appear, independent clinicians cannot inspect how dropouts were handled, how adverse events were classified, or what happened in subgroups. Treat them as a trailer, not the film.

Mechanistic and animal studies (supportive, not decisive). The rationale for adding glucagon rests on cell, rodent and short human physiology studies. These explain why the drug might work; they do not establish that it does in people over years.

Comparisons with other drugs (indirect, weak). No trial has yet randomized people between survodutide and semaglutide or tirzepatide. Any ranking you read online is a cross-trial comparison between studies with different populations, durations and definitions, and such comparisons are notoriously unreliable.

Hard outcomes (not yet available). There is currently no published evidence that survodutide reduces heart attacks, strokes, deaths, cirrhosis or liver transplants. A dedicated cardiovascular outcomes trial exists to find out.

A fair one-line verdict: promising, moderately strong early data on surrogate measures, with the decisive questions still open.

Survodutide vs semaglutide, tirzepatide and liraglutide: how the glucagon GLP-1 dual agonist compares

The table below sets survodutide alongside the medicines people most often compare it with. The weight figures come from each drug’s main published trial and are not head-to-head results; populations, durations and analysis methods differ, so read across rows with caution.

Medicine	Receptors targeted	Status (early 2026)	Headline weight result in main trial	Liver disease evidence
Survodutide	Glucagon + GLP-1	Investigational, phase 3	Up to ~15% at 46 weeks (phase 2)	Phase 2 MASH: up to 83% histologic improvement
Semaglutide	GLP-1 only	Approved for obesity and type 2 diabetes	~15% at 68 weeks (phase 3)	Phase 3 MASH trial positive; regulatory review for MASH
Tirzepatide	GIP + GLP-1	Approved for obesity and type 2 diabetes	~21% at 72 weeks (phase 3)	Phase 2 MASH trial positive
Liraglutide	GLP-1 only	Approved for obesity and type 2 diabetes	~8% at 56 weeks (phase 3)	Small early-phase MASH study
Retatrutide	Glucagon + GIP + GLP-1	Investigational, phase 3	Up to ~24% at 48 weeks (phase 2)	Phase 2 liver fat data; MASH trials ongoing

Two patterns stand out. Weight loss tends to climb as more receptors are added, from liraglutide’s single target to retatrutide’s three, though more receptors also means more ways to cause side effects. And survodutide’s distinctive card is the liver: its glucagon component is the reason its MASH data drew attention, while its phase 2 weight figure sits in the same neighborhood as semaglutide’s rather than clearly above tirzepatide’s.

What the table cannot show is tolerability, durability beyond a year, or outcomes that matter most, such as cardiovascular events. For approved medicines, MedlinePlus and the NHS carry current patient information; for the investigational ones, the trial publications on PubMed remain the only reliable source.

Is survodutide better than tirzepatide?

Nobody knows, and anyone who tells you otherwise is guessing. The question is reasonable, because tirzepatide currently holds the largest published weight loss of any approved medicine, and survodutide is the challenger with the liver story. But the only legitimate way to answer it is a trial that randomizes the same kinds of people to one drug or the other, and no such trial has been published.

Comparing the numbers that do exist is tricky for several reasons. Tirzepatide’s headline figure came from a 72-week phase 3 trial; survodutide’s came from a 46-week phase 2 trial that ended while weight was still dropping. The trials used different rules for handling people who stopped early. Participants differed in starting weight and background. Even a few weeks of extra follow-up can shift a mean weight loss figure by several percentage points.

On liver disease the comparison flips in survodutide’s favor on current evidence, since its MASH biopsy data are more extensive than tirzepatide’s phase 2 results, but tirzepatide’s trial was also positive, and neither has long-term outcome data. On side effects, both drugs produce the gastrointestinal effects common to the class, and survodutide carries the additional question of heart rate increases associated with glucagon activity, which the larger trials are tracking.

The honest framing is that these are different tools whose relative value will depend on the person: someone whose main concern is advanced liver scarring may eventually weigh the evidence differently from someone whose main goal is weight reduction with an established safety record. That weighing is clinical judgment, and it belongs to the treating clinician with the full picture of a patient’s history, not to a comparison chart. For now, tirzepatide is prescribable and survodutide is not, which settles most practical questions on its own.

What are survodutide's side effects in trials?

The side effect profile reported so far looks like a GLP-1 medicine with a few extra notes. In both phase 2 trials the most frequent adverse events were gastrointestinal: nausea, vomiting, diarrhea and constipation. These were mostly mild to moderate, clustered around dose increases, and tended to ease over weeks. They were also the main reason people left the studies early, which is a meaningful finding in itself, since a drug people cannot stay on delivers no benefit.

Glucagon receptor activation brings its own considerations. Increases in resting heart rate of a few beats per minute were observed, consistent with what has been seen across the glucagon-containing class. Whether a small persistent rise in heart rate matters for cardiovascular risk over years is unknown, and it is one of the reasons a dedicated cardiovascular outcomes trial is part of the phase 3 program.

Because glucagon raises blood sugar, trials have watched glucose closely. In adults without diabetes, average glucose markers did not worsen. In people with type 2 diabetes, the balance is being formally tested in a phase 3 study; early data suggested glucose control improved overall, but that needs confirmation.

Class-wide cautions that apply to all GLP-1 based medicines carry over as questions for survodutide: pancreatitis, gallbladder problems linked to rapid weight loss, dehydration from persistent vomiting, and a precautionary warning about thyroid C-cell tumors derived from rodent studies. None of these were signaled as new problems in phase 2, but a few hundred participants cannot detect rare events. Harvard Health’s summary of GLP-1 side effects explains the shared background well.

Side effect information for an investigational drug is, by definition, incomplete. Rare harms typically surface only after tens of thousands of people have used a medicine, which is exactly why approval is staged.

Is survodutide approved? Phase 3 trials and regulatory status

Survodutide is not approved for any use in any country. It is an investigational medicine, which means it can only be legally given to people enrolled in clinical trials under medical supervision. It is not available by prescription, it has no official patient leaflet, and no regulator has reviewed its complete safety data.

The phase 3 program is large. SYNCHRONIZE-1 studies adults with obesity or overweight and weight-related conditions but without diabetes; SYNCHRONIZE-2 studies adults with obesity and type 2 diabetes; SYNCHRONIZE-CVOT follows people at elevated cardiovascular risk to see whether the drug changes rates of heart attack, stroke and cardiovascular death. On the liver side, LIVERAGE enrolls adults with MASH and moderate to advanced fibrosis, and a companion study includes people with compensated cirrhosis, the earliest stage of cirrhosis in which the liver still functions adequately. These trials began between 2023 and 2024, and because liver outcomes take years to accumulate, the liver program is expected to run well beyond the obesity readouts.

Breakthrough Therapy designation, granted for MASH with fibrosis in 2024, is often misread. It is a procedural status that gives the developer more frequent meetings with the FDA and the possibility of a faster review. It is granted on the strength of preliminary evidence and is withdrawn if later data disappoint. It is not an endorsement of safety or effectiveness.

A separate point needs stating plainly. Vials or powders labeled survodutide sold by online sellers as research chemicals are unregulated products of unknown identity, purity and sterility. They are not the trial drug, they are not for human use, and no clinician can safely supervise their use because there is no verified product to supervise. Investigational medicines reach patients through trials, and only through trials.

What are some examples of glucagon agonist drugs, and which is the newest weight loss peptide?

Glucagon receptor agonists fall into two very different groups, and the distinction clears up a lot of confusion.

The first group is glucagon used as glucagon. Injectable and nasal glucagon products, along with the longer-acting analog dasiglucagon, are rescue treatments for severe hypoglycemia, the dangerous low blood sugar that can occur in people taking insulin. They work fast, last briefly, and have nothing to do with weight. They have been used for decades.

The second group is the newer family of engineered peptides that include glucagon activity alongside GLP-1 for metabolic disease. Survodutide is the most advanced dual glucagon/GLP-1 agonist in development. Others in the same category include mazdutide, which has been studied mainly in Asia, and cotadutide, an earlier dual agonist whose development was discontinued after modest results. Retatrutide goes one step further as a triple agonist, adding GIP to glucagon and GLP-1, and is also in phase 3 trials. Several more candidates are at earlier stages.

So which is the newest weight loss peptide? That depends on what counts. Among approved medicines, tirzepatide is the most recent, cleared for weight management in late 2023. Among investigational agents, retatrutide and survodutide are the two most watched, with orforglipron, a non-peptide GLP-1 taken by mouth, also drawing attention because it is a tablet rather than an injection. Newest does not mean best; it means least tested. Every approved drug in this field was once the newest, and each one gathered years of safety experience before reaching routine use.

A useful way to think about the whole family is a dial. Liraglutide and semaglutide turn one receptor. Tirzepatide and survodutide turn two, with different second choices. Retatrutide turns three. Each added receptor is a bet that more metabolic levers will produce more benefit without tipping into more harm, and each bet has to be tested separately.

Common myths about survodutide, corrected

Myth: survodutide is available now if you know where to look. It is not. No regulator has approved it, and no pharmacy can dispense it. Products marketed online under its name are unverified chemicals, not medicine.

Myth: it is proven to beat tirzepatide. No head-to-head trial exists. The phase 2 weight figure for survodutide is lower than tirzepatide’s phase 3 figure, but the trials differ in length and design, so neither direction of claim is supported.

Myth: glucagon in a weight loss drug will send blood sugar soaring. The GLP-1 component counterbalances glucagon’s effect on glucose. In the phase 2 obesity trial, glucose markers did not worsen. The combination is being formally tested in people with type 2 diabetes to confirm that balance.

Myth: it reverses liver disease. The MASH trial showed improvement in inflammation on biopsy in most participants and fibrosis improvement in about half, over 48 weeks. That is an encouraging surrogate result. Whether it prevents cirrhosis, liver failure or liver cancer has not been shown and will take years to establish.

Myth: it has no side effects because it is natural. It is a synthetic peptide, and gastrointestinal side effects were common enough that a notable share of trial participants stopped taking it. Heart rate increases were also observed.

Myth: the weight loss is permanent. No trial has studied what happens after stopping survodutide. For every related medicine studied so far, weight regain after discontinuation has been the rule rather than the exception, which is why obesity specialists describe these as long-term treatments for a chronic condition rather than a course.

Myth: Breakthrough Therapy designation means the FDA has found it safe. The designation speeds up communication during development. It is based on preliminary data and says nothing about final safety.

When to see a doctor

Because survodutide is available only inside clinical trials, the most relevant appointment for most readers is not about the drug at all. It is about the conditions it targets.

Fatty liver disease rarely causes symptoms until it is advanced, and it is usually found through routine blood tests or imaging done for other reasons. If you have type 2 diabetes, obesity, high triglycerides or metabolic syndrome, ask your clinician whether your liver has been assessed. Simple blood-test scores and a painless ultrasound-based scan can estimate scarring without a biopsy. The NIH’s liver disease pages explain who is at higher risk.

Seek prompt medical care if you notice yellowing of the skin or eyes, dark urine, pale stools, swelling of the abdomen or legs, confusion or unusual drowsiness, or vomiting blood. These can signal advanced liver disease and need same-day evaluation.

If you are enrolled in a survodutide trial or taking any GLP-1 based medicine, contact the trial team or prescriber urgently for severe or persistent abdominal pain, especially pain radiating to the back with vomiting, which can indicate pancreatitis; for vomiting or diarrhea lasting more than a day or two, because dehydration can harm the kidneys; for pain in the upper right abdomen, fever or jaundice, which may point to gallbladder trouble; for a racing or irregular heartbeat, fainting or chest pain; for a lump or swelling in the neck, hoarseness or difficulty swallowing; or for signs of severe low blood sugar if you also take insulin or a sulfonylurea.

If you are interested in survodutide, the right conversation is with your own clinician about whether a clinical trial is appropriate and how to find one through official registries. Never adjust, stop or add any medicine based on trial news. Every decision about weight or liver treatment, including whether an approved alternative suits you now, belongs with the clinician who knows your history.

Frequently asked questions

Is survodutide better than tirzepatide?

There is no evidence either way, because the two have never been compared in the same trial. Tirzepatide’s published phase 3 weight loss of about 21 percent is higher than survodutide’s phase 2 figure of about 15 percent, but the trials differed in length, design and population. Survodutide has more extensive liver biopsy data. Only a head-to-head randomized trial could settle the question, and the choice between approved options rests with your clinician.

Is liraglutide long acting or short acting?

Liraglutide is classed as a long-acting GLP-1 receptor agonist. Natural GLP-1 lasts about two minutes in the blood; liraglutide is modified to bind to a blood protein, giving it a half-life of roughly 13 hours. That places it between short-acting agents such as exenatide, which last a few hours, and the newer agents such as semaglutide, tirzepatide and survodutide, whose half-lives stretch to several days.

What is the newest weight loss peptide?

Among approved medicines, tirzepatide is the most recent, cleared for weight management in late 2023. Among investigational agents, survodutide and retatrutide are the most advanced, both in phase 3 trials, with retatrutide targeting three receptors and survodutide two. Newest means least tested, not best; each approved drug accumulated years of safety data before reaching routine use, and the investigational ones have not yet done so.

What are some examples of glucagon agonist drugs?

They fall into two groups. Rescue glucagon products, including the analog dasiglucagon, treat severe low blood sugar and act within minutes. The second group pairs glucagon with GLP-1 for metabolic disease: survodutide and mazdutide are dual agonists in late-stage trials, cotadutide was an earlier dual agonist that was discontinued, and retatrutide is a triple agonist adding GIP. None of the second group is approved.

Does survodutide work for fatty liver disease?

Phase 2 data are encouraging but not conclusive. In 293 adults with biopsy-confirmed MASH, up to 83 percent on survodutide showed improved liver inflammation without worsening scarring over 48 weeks, versus 18 percent on placebo, and about half showed at least one stage of fibrosis improvement. Whether these biopsy changes prevent cirrhosis or liver failure is unknown and is the subject of the ongoing phase 3 LIVERAGE trials.

What are the side effects of survodutide?

Nausea, vomiting, diarrhea and constipation were the most common side effects in phase 2 trials, mostly mild to moderate and clustered around dose increases, though they led a notable share of participants to stop. Small increases in resting heart rate were also seen, consistent with glucagon activity. Rarer class concerns such as pancreatitis and gallbladder problems cannot be assessed in trials of a few hundred people and await larger data.

Is survodutide approved anywhere?

No. Survodutide is investigational and has not been approved by any regulator for any condition. It received FDA Breakthrough Therapy designation for MASH with fibrosis in 2024, which speeds up regulatory communication but is not an approval and does not confirm safety. It can be given only to people enrolled in clinical trials, and it has no official prescribing information or patient leaflet.

Can I buy survodutide online as a research peptide?

No legitimate route exists. Products sold online under the name survodutide are unregulated chemicals with unverified identity, purity and sterility; they are not the trial medicine and are not for human use. Because they are unverified, no clinician can safely supervise their use. People interested in survodutide should ask their own clinician about clinical trial eligibility through official trial registries.

Does the glucagon in survodutide raise blood sugar?

Not in the trials so far. Glucagon on its own raises blood sugar, but the GLP-1 component of survodutide increases insulin release when glucose is high, counterbalancing that effect. In the phase 2 obesity trial, glucose markers did not worsen. A dedicated phase 3 trial in people with type 2 diabetes is testing whether that balance holds, and results from it are needed before firm conclusions.

How does a glucagon GLP-1 dual agonist differ from a regular GLP-1 drug?

A standard GLP-1 drug such as semaglutide reduces appetite, slows stomach emptying and supports insulin release. A dual agonist adds glucagon receptor activation, which increases fat breakdown in the liver and modestly raises energy expenditure. The intended result is similar weight loss plus a direct effect on liver fat, which is why survodutide is being tested for MASH. The trade-off under study is whether glucagon activity adds side effects.

References

• PubMed: survodutide clinical trial publications (NIH National Library of Medicine)
• NIH NIDDK: Nonalcoholic Fatty Liver Disease and NASH (MASLD and MASH)
• Cleveland Clinic: GLP-1 agonists
• MedlinePlus: Liraglutide injection

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.